Denial rates on hereditary cancer panel claims have hit as high as 80% under certain payer prior-auth programs, and OIG opened a dedicated new audit in June 2026 into the $3.6 billion Medicare spends yearly on genetic tests.
Common Billing Challenges
These are the six billing failure points we see most often in genetic and molecular testing labs and ordering practices — and the ones our team resolves systematically from day one.
MACs using MolDX require a unique Z-Code alongside the CPT or HCPCS code — without one, or without a completed Technical Assessment, the claim is denied for identification failure.
Tier 1 (81161-81392), Tier 2 (81400-81408), GSP (81410-81471), MAAA (81490-81599), and PLA (0001U+) each cover a different test type — picking the wrong family is a routine denial trigger.
UHC, Anthem, and other major payers run different genetic testing prior auth programs that update policy frequently and diverge significantly from one another.
NCD 90.2 and MolDX LCDs exclude repeat testing of the same genetic content — ordering without checking a patient's full testing history triggers automatic denial.
A signed lab requisition alone doesn't establish medical necessity — the physician's intent to order needs to be documented in the medical record itself, not just on a form.
The 2019 "Operation Double Helix" takedown remains the largest genetic-testing fraud case on record, and payers now treat unsolicited marketing and questionable ordering patterns as automatic red flags.
Key Procedure Codes
Our coders hold specialty-specific credentials and train continuously on the codes that drive the most revenue — and the most denials — in genetic and molecular testing.
| CPT Code | Description | Common Issue |
|---|---|---|
| 81161-81392 | Tier 1 — analyte-specific single-gene tests | Must match the lab's actual test methodology |
| 81400-81408 | Tier 2 — nine complexity levels for less common genes | Complexity level must match the lab report, not just the gene name |
| 81410-81471 | GSP — exome, genome, multi-gene panel sequencing | High-cost claims draw the most payer scrutiny |
| 81490-81599 | MAAA — multianalyte assays with algorithmic analysis | Bills the algorithm's output, not the individual analytes |
| 0001U+ | PLA — proprietary laboratory analyses | Requires the current quarterly AMA PLA code plus a registered Z-Code |
| DEX Z-Code | MolDX unique test identifier | Required alongside the CPT code across MolDX's 28-state MAC footprint |
Why Rcmaxis
We're not a generalist billing service that added a specialty module. Our team is built around specialty-specific expertise.
Every coder on your account holds the specialty coding credential relevant to genetic and molecular testing — not a generic CPC only.
Built to outperform the up-to-80% denial rates reported on hereditary cancer panels under certain payer prior-auth programs. Fewer rejections means faster payment.
Full LIS integration, payer enrollment verification, and Z-Code registration review in 2 weeks — with zero disruption to your testing pipeline.
One point of contact who knows your lab, your payers, and your billing history — available for weekly calls and monthly performance reviews.
Month-to-month engagement. We earn your business every month by improving your collections — not by locking you in.
Live visibility into your collections, denial rate, aging AR, and payer performance — updated daily, reviewed monthly with your account team.
Straight answers to what labs and ordering practices usually ask before they switch.
Free revenue assessment for qualified labs and ordering practices. We audit your last 90 days of claims, identify every revenue leak, and show you a clear path to better collections — at no cost.